Literature DB >> 15919659

Neurodegeneration in heterozygous Niemann-Pick type C1 (NPC1) mouse: implication of heterozygous NPC1 mutations being a risk for tauopathy.

Wenxin Yu1, Mihee Ko, Katsuhiko Yanagisawa, Makoto Michikawa.   

Abstract

Niemann-Pick type C1 (NPC1) disease is an autosomal recessive, fatal disorder characterized by a defect in cholesterol trafficking and progressive neurodegeneration. The disease is predominantly caused by mutations in the NPC1 gene; however, it has been assumed that heterozygous NPC1 mutations do not cause any symptoms. Here we demonstrate that cholesterol accumulation does not occur in young mouse brains; however, it does in aged (104-106-week-old) NPC1+/- mouse brains. In addition, Purkinje cell loss was observed in aged NPC1+/- mouse cerebellums. Immunoblot analysis using anti-phospho-tau antibodies (AT-8, AT-100, AT-180, AT-270, PHF-1, and SMI-31) demonstrates the site-specific phosphorylation of tau at Ser-199, Ser-202, Ser-212, and Thr-214 in the brains of aged NPC1+/- mice. Mitogen-activated protein kinase, a potential serine kinase known to phosphorylate tau, was activated, whereas other serine kinases, including glycogen synthase kinase 3beta, cyclin-dependent kinase 5, or stress-activated protein kinase/c-Jun N-terminal kinase were not activated. Cholesterol level in the lipid raft isolated from the cerebral cortices, ATP level, and ATP synthase activity in the cerebral cortices significantly decreased in the aged NPC1+/- brains compared with those in the NPC1+/+ brains. All of these changes observed in NPC1+/- brains were determined to be associated with aging and were not observed in the age-matched NPC1+/+ brains. These results clearly demonstrate that heterozygous NPC1 impairs neuronal functions and causes neurodegeneration in aged mouse brains, suggesting that human heterozygous NPC1 mutations may be a risk factor for neurodegenerative disorders, such as tauopathy, in the aged population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15919659     DOI: 10.1074/jbc.M503922200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease.

Authors:  Forbes D Porter; David E Scherrer; Michael H Lanier; S Joshua Langmade; Vasumathi Molugu; Sarah E Gale; Dana Olzeski; Rohini Sidhu; Dennis J Dietzen; Rao Fu; Christopher A Wassif; Nicole M Yanjanin; Steven P Marso; John House; Charles Vite; Jean E Schaffer; Daniel S Ory
Journal:  Sci Transl Med       Date:  2010-11-03       Impact factor: 17.956

2.  Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects.

Authors:  Jennifer C Naylor; Jason D Kilts; Christine M Hulette; David C Steffens; Dan G Blazer; John F Ervin; Jennifer L Strauss; Trina B Allen; Mark W Massing; Victoria M Payne; Nagy A Youssef; Lawrence J Shampine; Christine E Marx
Journal:  Biochim Biophys Acta       Date:  2010-05-19

Review 3.  Cellular cholesterol homeostasis and Alzheimer's disease.

Authors:  Ta-Yuan Chang; Yoshio Yamauchi; Mazahir T Hasan; Catherine Chang
Journal:  J Lipid Res       Date:  2017-03-15       Impact factor: 5.922

Review 4.  The pathogenesis of Niemann-Pick type C disease: a role for autophagy?

Authors:  Chris D Pacheco; Andrew P Lieberman
Journal:  Expert Rev Mol Med       Date:  2008-09-10       Impact factor: 5.600

5.  Neurological Dysfunction in Early Maturity of a Model for Niemann-Pick C1 Carrier Status.

Authors:  Ya Hui Hung; Mark Walterfang; Leonid Churilov; Lisa Bray; Laura H Jacobson; Kevin J Barnham; Nigel C Jones; Terence J O'Brien; Dennis Velakoulis; Ashley I Bush
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

6.  Variation in NPC1, the gene encoding Niemann-Pick C1, a protein involved in intracellular cholesterol transport, is associated with Alzheimer disease and/or aging in the Polish population.

Authors:  Robert P Erickson; Katherine Larson-Thomé; Lyndon Weberg; Aleksandra Szybinska; Malgorzata Mossakowska; Maria Styczynska; Maria Barcikowska; Jacek Kuznicki
Journal:  Neurosci Lett       Date:  2008-09-24       Impact factor: 3.046

Review 7.  Current concepts in the neuropathogenesis of mucolipidosis type IV.

Authors:  Lauren C Boudewyn; Steven U Walkley
Journal:  J Neurochem       Date:  2018-08-30       Impact factor: 5.372

8.  Decreased Npc1 gene dosage in mice is associated with weight gain.

Authors:  David Jelinek; Randall A Heidenreich; Robert P Erickson; William S Garver
Journal:  Obesity (Silver Spring)       Date:  2009-11-12       Impact factor: 5.002

9.  The role of decreased levels of Niemann-Pick C1 intracellular cholesterol transport on obesity is reversed in the C57BL/6J, metabolic syndrome mouse strain: a metabolic or an inflammatory effect?

Authors:  Ivan Borbon; Erin Campbell; Wangjing Ke; Robert P Erickson
Journal:  J Appl Genet       Date:  2012-05-15       Impact factor: 3.240

Review 10.  Do GWAS and studies of heterozygotes for NPC1 and/or NPC2 explain why NPC disease cases are so rare?

Authors:  Robert P Erickson
Journal:  J Appl Genet       Date:  2018-09-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.